JHL Biotech, Selexis SA Provide Speedy Drug Manufacturing Services

JHL Biotech and Selexis SA are collaborating to provide a seamless solution for the development and cGMP manufacturing of biologic drugs.

AsianScientist (Dec. 12, 2013) – JHL Biotech, Inc., a provider of biopharmaceutical process development and manufacturing services, and Selexis SA have signed an agreement to provide biopharmaceutical customers a seamless solution for the development and cGMP manufacturing of biologic drugs.

The alliance will allow biopharmaceutical customers to quickly go from drug candidate DNA to active pharmaceutical ingredient (API) into clinical development and commercialization.

Selexis will provide the SURE CHO-M™ mammalian clonal cell lines, and JHL Biotech will provide process development and manufacturing that follows current good manufacturing practices (cGMP) at their facilities in Hsinchu, Taiwan and Wuhan, China.

In its first joint effort, JHL Biotech and Selexis were able to develop and successfully transfer a biosimilar antibody product. Selexis generated the SURE CHO-M™ cell line that is now undergoing JHL Biotech’s comprehensive process development.

JHL Biotech is manufacturing the biosimilar drug at its facility in Hsinchu, Taiwan. The facility is outfitted with GE Healthcare’s technology FlexFactory® and includes two 500L single-use bioreactors.

“Biopharmaceutical companies now can turn to JHL Biotech and Selexis for a reliable, rapid process to get products to market in China and the rest of the world,” said Racho Jordanov, CEO of JHL Biotech.

“We are especially pleased at how fast we were able to provide JHL’s customer a clonal cell line expressing over 5 g/L at Selexis,” said Dr. Igor Fisch, CEO, Selexis SA. “By seamlessly combining JHL Biotech and Selexis’ unique technologies and know-how, it is now possible to save our customers both time and money with their biologic development programs. Moreover, the JHL Biotech and Selexis alliance will allow biopharmaceutical companies to cost effectively develop safe biologic drugs for the Chinese market.”

——

Source: JHL Biotech Inc.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist